title: Attention-deficit/hyperactivity disorder-specific quality of life with triple-bead mixed amphetamine salts (SPD465) in adults: results of a randomized, double-blind, placebo-controlled study.
abstract: OBJECTIVE
  To assess the quality of life (QOL) in adults with attention-deficit/hyperactivity disorder (ADHD) given triple-bead mixed amphetamine salts (MAS), a long-acting amphetamine formulation designed for a duration of action of up to 16 hours.
  
  
  METHODS
  274 adults with ADHD (DSM-IV-TR criteria) were randomly assigned to 7 weeks of double-blind treatment with an optimal dose of triple-bead MAS (12.5 mg to 75 mg) (N = 137) or placebo (N = 137). As a secondary objective of this study, QOL was assessed on the basis of self-reported Adult ADHD Impact Module (AIM-A) scores, describing ADHD-specific QOL in 6 domains and global QOL (questions 1-4). To assess safety, data were collected on adverse events, vital signs, electrocardiograms, laboratory tests, and sleep quality. The trial was conducted from January 2005 to June 2005.
  
  
  RESULTS
  Statistically significant improvement between triple-bead MAS and placebo was observed in all 6 ADHD-specific AIM-A subscales. In addition, statistically significant improvement in global QOL between triple-bead MAS and placebo was seen, based on AIM-A question 1 (p = .0006) and question 4 (p = .0001). Patients' age, gender, race, and prior use of stimulant medication were not found to significantly affect AIM-A subscale scores. The most common treatment-emergent adverse events with triple-bead MAS (insomnia, dry mouth, decreased appetite, headache, and weight decreased) were consistent with amphetamine treatment, and their incidence generally decreased with time.
  
  
  CONCLUSIONS
  Adults with ADHD showed significantly improved QOL for both ADHD-specific and global measures with triple-bead MAS in comparison to placebo, based on AIM-A scores. Treatment-emergent adverse events were mostly mild to moderate in intensity and were consistent with amphetamine treatment.
  
  
  BACKGROUND
  clinicaltrials.gov Identifier: NCT00150579.
authors.affiliation: Massachusetts General Hospital, Pediatric Psychopharmacology Research Unit, 55 Fruit St., Warren 705, Boston, MA 02114, USA. spencer@helix.mgh.harvard.edu
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Spencer
authors.forename: Jeanne M
authors.initials: JM
authors.lastname: Landgraf
authors.forename: Lenard A
authors.initials: LA
authors.lastname: Adler
authors.forename: Richard H
authors.initials: RH
authors.lastname: Weisler
authors.forename: Colleen S
authors.initials: CS
authors.lastname: Anderson
authors.forename: Sharon H
authors.initials: SH
authors.lastname: Youcha
mesh_terms: D000328:Adult; D000661:Amphetamine / Q000008:administration & dosage* / Q000009:adverse effects; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000008:administration & dosage* / Q000009:adverse effects; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D016018:Least-Squares Analysis; D008297:Male; D008875:Middle Aged; D011788:Quality of Life
chemical_list: D000697:Central Nervous System Stimulants; D003692:Delayed-Action Preparations; D000661:Amphetamine